期刊
MOLECULAR ONCOLOGY
卷 13, 期 2, 页码 171-184出版社
WILEY
DOI: 10.1002/1878-0261.12391
关键词
circulating tumor DNA; concordance; melanoma; promoter
类别
资金
- NHMRC [1117911]
- Cancer Council Grant [1100249]
- Spinnaker Foundation
- Perpetual Foundation
- Cancer Research Trust
- NHMRC Senior Principal Research Fellowship
- ECU Early Career Research grant
- Department of Health Western Australia
- National Health and Medical Research Council of Australia [1117911] Funding Source: NHMRC
Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for noninvasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study, we compared the mutation profiles of tumor biopsies and plasma ctDNA from metastatic melanoma patients using custom sequencing panels targeting 30 melanoma-associated genes. Somatic mutations were identified in 20 of 24 melanoma biopsies, and 16 of 20 (70%) matched-patient plasmas had detectable ctDNA. In a subgroup of seven patients for whom matching tumor tissue and plasma were sequenced, 80% of the mutations found in tumor tissue were also detected in ctDNA. However, TERT promoter mutations were only detected by ddPCR, and promoter mutations were consistently found at lower concentrations than other driver mutations in longitudinal samples. In vitro experiments revealed that mutations in promoter regions of TERT and DPH3 are underrepresented in ctDNA. While the results underscore the utility of using ctDNA as an alternative to tissue biopsy for genetic profiling and surveillance of the disease, our study highlights the underrepresentation of promoter mutations in ctDNA and its potential impact on quantitative liquid biopsy applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据